Bellmunt J, Wit R De, Vaughn DJ, et al. Pembrolizumab as Second-Line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376(11): 1015-26.
Powles T, Durán I, van der Heijden MS, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet 2017; 6736(17): 1-11.
Faltas BM, Prandi D, Tagawa ST, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet 2016 Dec 17; 48(12): 1490-9.
Gerullis H, Wawroschek F, Köhne C-H, Ecke TH. Vinflunine in the treatment of advanced urothelial cancer: Clinical evidence and experience. Ther Adv Urol 2017; 9(1): 28-35.
Siefker-Radtke AO, Necchi A, Park SH, et al. First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt). J Clin Oncol 2018; 36(15_suppl): 4503.
Culine S, Theodore C, De Santis M, et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006; 94(10): 1395-401.
Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27(27): 4454-61.
Bellmunt J, Fougeray R, Rosenberg JE, et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Ann Oncol 2013; 24(6): 1466-72.
Di Lorenzo G, Buonerba C, Bellelli T, et al. Third-Line Chemotherapy for metastatic urothelial cancer: A retrospective observational study. Medicine (Baltimore) 2015; 94(51): e2297.
Palacka P, Mego M, Obertova J, Chovanec M, Sycova-Mila Z, Mardiak J. The first Slovak experience with second-line vinflunine in advanced urothelial carcinomas. Klin Onkol 2014; 27(6): 429-33.
Hegele A, Goebell P, Matz U, Neuhaus T. Monotherapy with Intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: A retrospective analysis of german routine data. Urol Int 2014; 92(2): 174-9.
Brousell SC, Fantony JJ, Van Noord MG, Harrison MR, Inman BA. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: An evidence-based review of safety, efficacy, and place in therapy. Core Evid 2018; 13: 1-12.
Pond GR, Niegisch G, Rosenberg JE, et al. New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. J Clin Oncol 2018; 36(6): 413.
García-Donas J, Font A, Pérez-Valderrama B, et al. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): A multicentre, randomised, controlled, open. Lancet Oncol 2017; 18(5): 672-81.
De Santis M, Wiechno P, Bellmunt J, Lucas C, Su W, Albiges L. Vinflunine- gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: Results of an international randomized phase II trial (JASINT1). Ann Oncol 2016; 27: 449-54.
Gerullis H, Eimer C, Ecke TH, Georgas E, Arndt C, Otto T. Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy. Anticancer Drugs 2013; 24(4): 422-5.
Pappot H, von der Maase H, Ullén A, Agerbæk M. Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy- results of an exploratory phase I study. Invest New Drugs 2018; 36(4): 615-8.
Sonpavde G, Pond GR, Choueiri TK, et al. Single-agent taxane versus taxane-containing combination chemotherapy as salvage therapy for advanced urothelial Carcinoma. Eur Urol 2016; 69(4): 634-41.
Vaughn DJ, Srinivas S, Stadler WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study. Cancer 2009; 115(18): 4110-7.
Schinzari G, Rossi E, Pierconti F, et al. Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium. Oncotarget 2018; 9(9): 8765-71.
McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15(5): 1853-7.
Kim YS, Lee S, Park SH, et al. A Phase II study of weekly docetaxel as second-line chemotherapy in patients with metastatic urothelial carcinoma. Clin Genitourin Cancer 2016; 14(1): 76-81.
Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20(4): 937-40.
Akaza H, Naito S, Usami M, Miki T, Miyanaga N, Taniai H. Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after cisplatin-containing therapy: A Japanese experience. Jpn J Clin Oncol 2007; 37(3): 201-6.
Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development. A review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001; 40(2): 159-73.
Guglieri-López B, Pérez-Pitarch A, Porta-Oltra B, Ferriols-Lisart F, Climente-Martí M, Alós-Almiñana M. Effectiveness, toxicity, and economic evaluation of vinflunine for the treatment of patients with transitional cell carcinoma in the Spanish outpatient setting. Anticancer Drugs 2015; 26(8): 860-5.
Sarfaty M, Hall PS, Chan KKW, et al. Cost-effectiveness of pembrolizumab in second-line advanced bladder cancer. Eur Urol 2018; 74(1): 57-62.
Castellano D, Puente J, de Velasco G, et al. Safety and effectiveness of vinflunine in patients with metastatic transitional cell carcinoma of the urothelial tract after failure of one platinum-based systemic therapy in clinical practice. BMC Cancer 2014; 14(1): 779.
Pistamaltzian N, Tzannis K, Pissanidou V, et al. Treatment of relapsed urothelial bladder cancer with vinflunine. Anticancer Drugs 2016; 27(1): 48-53.